175 related articles for article (PubMed ID: 38415112)
21. Noninvasive Left Ventricular Myocardial Work in Patients with Chronic Aortic Regurgitation and Preserved Left Ventricular Ejection Fraction.
Meucci MC; Butcher SC; Galloo X; van der Velde ET; Marsan NA; Bax JJ; Delgado V
J Am Soc Echocardiogr; 2022 Jul; 35(7):703-711.e3. PubMed ID: 35091069
[TBL] [Abstract][Full Text] [Related]
22. The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial).
Biering-Sørensen T; Lassen MCH; Shah A; Claggett B; Zile M; Pieske B; Pieske-Kraigher E; Voors A; Shi V; Lefkowitz M; Packer M; McMurray JJV; Solomon SD;
J Card Fail; 2023 Jun; 29(6):968-973. PubMed ID: 37031887
[TBL] [Abstract][Full Text] [Related]
23. Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients.
Öz TK; Abdelnabi M; Fiore C; Almaghraby A; Cihan D; Babazade N; Haseeb Raza Naqvi S; Omar B; Dağdeviren B
Minerva Cardiol Angiol; 2022 Aug; 70(4):431-438. PubMed ID: 34713680
[TBL] [Abstract][Full Text] [Related]
24. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction.
Docherty KF; Campbell RT; Brooksbank KJM; Dreisbach JG; Forsyth P; Godeseth RL; Hopkins T; Jackson AM; Lee MMY; McConnachie A; Roditi G; Squire IB; Stanley B; Welsh P; Jhund PS; Petrie MC; McMurray JJV
Circulation; 2021 Jul; 144(3):199-209. PubMed ID: 33983794
[TBL] [Abstract][Full Text] [Related]
25. Study of stress-strain loops on cardiotoxicity related to immune checkpoint inhibitors.
Chunlan S; Bing Y; Xi W
Echocardiography; 2024 Jan; 41(1):e15746. PubMed ID: 38284683
[TBL] [Abstract][Full Text] [Related]
26. The Clinical Evolution of Diffuse Myocardial Fibrosis in Patients With Arterial Hypertension and Heart Failure With Mildly Reduced Ejection Fraction Treated by Olmesartan or Sacubitril / Valsartan.
Shulzhenko LV; Pershukov IV; Batyraliev TA; Karben ZA; Gurovich OV; Fettser DV; Kuznetsova TN; Ivanenkova EY; Akbalaeva BA; Rayimbek Uulu N N; Toygonbaev S; Mansharipova AT; Seidalin AO; Zyablova EI; Kalmatov RK; Imetova ZB; Vinogradskaia VV; Gaydukova EV
Kardiologiia; 2023 Dec; 63(12):31-38. PubMed ID: 38156487
[TBL] [Abstract][Full Text] [Related]
27. Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction.
Jiang J; Gao J; Zhang X; Li Y; Dang H; Liu Y; Chen W
Front Cardiovasc Med; 2023; 10():1097066. PubMed ID: 37034349
[TBL] [Abstract][Full Text] [Related]
28. A new approach to assess myocardial work by non-invasive left ventricular pressure-strain relations in hypertension and dilated cardiomyopathy.
Chan J; Edwards NFA; Khandheria BK; Shiino K; Sabapathy S; Anderson B; Chamberlain R; Scalia GM
Eur Heart J Cardiovasc Imaging; 2019 Jan; 20(1):31-39. PubMed ID: 30247622
[TBL] [Abstract][Full Text] [Related]
29. Myocardial Injury in Multiple Myeloma Patients With Preserved Left Ventricular Ejection Fraction: Noninvasive Left Ventricular Pressure-Strain Myocardial Work.
Liu Z; Zhang L; Liu M; Wang F; Xiong Y; Tang Z; Li Q; Lu Q; Liang S; Niu T; Huang H
Front Cardiovasc Med; 2021; 8():782580. PubMed ID: 35127857
[TBL] [Abstract][Full Text] [Related]
30. Early improvement of strain imaging parameters predicts long-term response to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: An observational prospective study.
Camilli M; Iannaccone G; Russo M; Meucci MC; Chiorazzo G; Natali R; Mango F; Bonanni A; Montone RA; Graziani F; Locorotondo G; Massetti M; Lanza GA; Aspromonte N; Crea F; Lombardo A
Int J Cardiol; 2023 Sep; 387():131110. PubMed ID: 37290664
[TBL] [Abstract][Full Text] [Related]
31. Reverse Remodeling Assessed by Left Atrial and Ventricular Strain Reflects Treatment Response to Sacubitril/Valsartan.
Moon MG; Hwang IC; Lee HJ; Kim SH; Yoon YE; Park JB; Lee SP; Kim HK; Kim YJ; Cho GY
JACC Cardiovasc Imaging; 2022 Sep; 15(9):1525-1541. PubMed ID: 36075612
[TBL] [Abstract][Full Text] [Related]
32. Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.
Ledwidge M; Dodd JD; Ryan F; Sweeney C; McDonald K; Fox R; Shorten E; Zhou S; Watson C; Gallagher J; McVeigh N; Murphy DJ; McDonald K
JAMA Cardiol; 2023 Apr; 8(4):366-375. PubMed ID: 36884247
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Myocardial Work of the Left Ventricle before and after PCI in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome by Pressure-Strain Loop Technology.
Ren F; Xue T; Tang G; Zhang M; Zhao J; Chen Y; Fan J; Yu M; Zhang J
Comput Math Methods Med; 2022; 2022():8026689. PubMed ID: 35664637
[TBL] [Abstract][Full Text] [Related]
34. Short-term effects of sacubitril/valsartan therapy on myocardial oxygen consumption and energetic efficiency of cardiac work in heart failure with reduced ejection fraction: A randomized controlled study.
Nesterov SV; Räty J; Nammas W; Maaniitty T; Galloo X; Stassen J; Laurila S; Vasankari T; Huusko J; Bax JJ; Saraste A; Knuuti J
Eur J Heart Fail; 2024 Jan; 26(1):117-126. PubMed ID: 37905338
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study.
Tsutsui H; Momomura SI; Saito Y; Ito H; Yamamoto K; Sakata Y; Desai AS; Ohishi T; Iimori T; Kitamura T; Guo W;
Circ J; 2021 Apr; 85(5):584-594. PubMed ID: 33731544
[TBL] [Abstract][Full Text] [Related]
36. Reference Values of Noninvasive Myocardial Work Indices Measured by Echocardiography in Healthy Children.
Cui C; Zheng Q; Li Y; Huang D; Hu Y; Wang Y; Liu R; Liu L; Zhang L
Front Pediatr; 2022; 10():792526. PubMed ID: 35783329
[TBL] [Abstract][Full Text] [Related]
37. Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study.
Acquaro M; Scelsi L; Pasotti B; Seganti A; Spolverini M; Greco A; Schirinzi S; Turco A; Sanzo A; Savastano S; Rordorf R; Ghio S
Vascul Pharmacol; 2023 Oct; 152():107196. PubMed ID: 37467909
[TBL] [Abstract][Full Text] [Related]
38. Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up.
Paolini C; Mugnai G; Dalla Valle C; Volpiana A; Ferraglia A; Frigo AC; Bilato C
Int J Cardiol Heart Vasc; 2021 Aug; 35():100821. PubMed ID: 34179333
[TBL] [Abstract][Full Text] [Related]
39. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
[TBL] [Abstract][Full Text] [Related]
40. The value of speckle-tracking stratified strain combined with myocardial work measurement in evaluating left ventricular function in patients with heart failure with preserved ejection fraction.
Lan J; Wang Y; Zhang R; Li J; Yu T; Yin L; Shao T; Lu H; Wang C; Xue L
Quant Imaging Med Surg; 2024 Mar; 14(3):2514-2527. PubMed ID: 38545041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
